Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain

Journal of Medicinal Chemistry

Volumn 48, Issue 13, 2005, Pages 4200-4203

  Dominguez, Esteban ^a   Iyengar, Smriti ^b   Shannon, Harlan E ^b   Bleakman, David ^b   Alt, Andrew ^b   Arnold, Brian M ^b   Bell, Michael G ^b   Bleisch, Thomas J ^b   Buckmaster, Jennifer L ^b   Castano, Ana M ^a   Del Prado, Miriam ^a   Escribano, Ana ^a   Filla, Sandra A ^b   Ho, Ken H ^b,c   Hudziak, Kevin J ^b   Jones, Carrie K ^b   Martinez Perez, Jose A ^a   Mateo, Ana ^a   Mathes, Brian M ^b   Mattiuz, Edward L ^b   Ogden, Ann Marie L ^b   Simmons, Rosa Maria A ^b   Stack, Douglas R ^b   Stratford, Robert E ^b   Winter, Mark A ^b   Wu, Zhipei ^b   Ornsteint, Paul L ^b   more..

^a CSIC   (Spain)

^b ELI LILLY AND COMPANY   (United States)

^c NPS Pharmaceutical Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSAICIN; CARRAGEENAN; FORMALDEHYDE; GLUTAMATE RECEPTOR 2; GLUTAMATE RECEPTOR 5; GLUTAMATE RECEPTOR 6; KAINIC ACID RECEPTOR; KAINIC ACID RECEPTOR ANTAGONIST; LY 457691; LY 458545; LY 467711; LY 525327; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; HUMAN CELL; HYPERALGESIA; LICKING; MALE; NONHUMAN; PAIN; RAT;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; AMINO ACIDS; ANALGESICS; ANIMALS; BIOLOGICAL AVAILABILITY; CELL LINE; DISEASE MODELS, ANIMAL; HUMANS; HYPERALGESIA; PAIN; RATS; RECEPTORS, AMPA; RECEPTORS, KAINIC ACID; RECOMBINANT PROTEINS; SPINAL CORD;

EID: 21244432731     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0491952     Document Type: Article

References (27)

1. Schoepp, D. D.; et al. Trends Pharmacol. Sci. 1993, 14, 13.
2. Collingridge, G. L.; Lester, R. A. J. Excitatory amino acid receptors in the vertebrate central nervous system. Pharmacol. Rev. 1989, 40, 143-210.
3. (a) Bleakman, D.; Lodge, D. Neuropharmacology of AMPA and KA receptors. Neuropharmacology 1998, 37, 1187-1204.
4. (b) Hollman, M.; Heinemann, S. Cloned glutamate receptors. Annu. Rev. Neurosci. 1994, 17, 31-108.
5. (c) Seeburg, P. H. The molecular biology of mammalian glutamate receptor channels. Trends Neurosci. 1993, 16, 359-365.
6. Agrawal, S. G.; Evans, R. H. The primary afferent depolarizing action of KA in the rat. Br. J. Pharmacol. 1986, 87, 345-355.
7. (a) Huettner, J. E. Glutamate receptor channels in DRG neurons: activation by KA and quisqualate and blockade of desensitization by concanavalin. Neuron 1990, 5, 255-266.
8. (b) Partin, K. M.; Patneau, D. K.; Winters, C. A.; Mayer, M. L.; Buonanno, A. Selective modulation of desensitization at AMPA versus KA receptors by cyclothiazide and concanavalin A. Neuron 1993, 11, 1069-1082.
9. (a) Li, P.; Wilding, T. J.; Kim, S. J.; Calejesan, A. A.; Huettner, J. E.; Zhuo, M. Kainate-receptor-mediated sensory synaptic transmission in mammaliam spinal cord. Nature 1999, 397, 161-164.
10. (b) Procter, M. J.; Houghton, A. K.; Faber, E. S. L.; Chizh, B. A.; Ornstein, P. L.; Lodge, D.; Headley, P. M. Actions of KA and AMPA selective glutamate receptor ligands on nociceptive processing in the spinal cord. Neuropharmacology 1998, 37, 1287-1297.
11. (c) Evans, R. H.; Long, S. K. Primary afferent depolarization in the rat spinal cord is mediated by pathways utilizing NMDA and non-NMDA receptors. Neurosci. Lett. 1989, 100, 231-236.
12. (d) Evans, R. H.; Evans, S. J.; Pook, P. C.; Sunter, D. C. A comparison of excitatory amino acid antagonists acting at primary afferent C fibers and motoneurons of the isolated spinal cord of the rat. Br. J. Pharmacol. 1987, 91, 531-537.
13. (a) Ornstein, P. L.; Arnold, M. B.; Augenstein, N. K.; Lodge, D.; Leander, J. D.; Schoepp, D. D. (3SR,4aRS,6RS,8aRS)-6-[2(1H-Tetrazol-5-yl)ethyl] decahydroisoquinoline-3-carboxylic acid: A structurally novel, systemically active, competitive AMPA receptor antagonist. J. Med. Chem. 1993, 36, 2046-2048.
14. (b) Ornstein, P. L.; Arnold, M. B.; Allen, N. K. Bleisch, T.; Borromeo, P. S.; Lugar, C. W.; Leander, J. D.; Lodge, D.; Schoepp, D. D. Structure-activity studies of 6-(tetrazolylalkyl)-substituted decahydroisoquinoline-3-carboxylic acid AMPA receptor antagonists. 1. Effects of stereochemistry, chain length, and chain substitution. J. Med. Chem. 1996, 39, 2219-2231.
15. (c) Ornstein, P. L.; Arnold, M. B.; Allen, N. K.; Bleisch, T.; Borromeo, P. S.; Lugar, C. W.; Leander, J. D.; Lodge, D.; Schoepp, D. D. Structure-activity studies of 6-(tetrazolylalkyl)-substituted decahydroisoquinoline-3-carboxylic acid AMPA receptor antagonists. 2. Effects of distal acid bioisosteric substitution, absolute stereochemical preferences, and in vivo activity. J. Med. Chem. 1996, 39, 2232-2244.
16. (a) Sang, C. N.; Hostetter, M. P.; Gracely, R. H.; Chappell, A. S.; Schoepp, D. D.; Lee, G.; Whitcup, S.; Caruso, R.; Max, M. B. AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans. Anesthesiology 1998, 89, 1060-1067.
17. (b) Gilron, I.; Max, M. B.; Lee, G. Booher, S. L.; Sang, C. N.; Chappell, A. S.; Dionne, R. A. Effects of the 2-amino-3-hydroxy-5-methyl-isoxazole- propionic acid/KA antagonist LY293558 on spontaneous and evoked postoperative pain. Clin. Pharmacol. Ther. 2000, 68, 320-327.
18. Bleisch, T.; Ornstein, P. L.; Allen, N. K.; Wright, R. A.; Lodge, D.; Schoepp, D. D. Structure-activity studies of aryl-spaced decahydroisoqmnoline-3- carboxylic acid AMPA receptor antagonists. Bioorg. Med. Chem. Lett. 1997, 7, 1161-1166.
19. Simmons, R. M. A.; Li, D. L.; Hoo, K. H.; Deverill, M.; Ornstein, P. L.; Iyengar, S. Kainate GluR5 receptor subtype mediates the nociceptive reponse to formalin in the rat. Neuropharmacology 1998, 37, 25-36.
20. Heapy, C. G.; Jamieson, A.; Russell, N. J. W. Afferent C-fiber and A-delta activity in models of inflammation. Br. J. Pharmacol. 1987, 90, 164P.
21. Filla, S. A.; Winter, M. A.; Johnson, K. W.; Bleakman, D.; Bell, M. G.; Bleisch, T. J.; Castano, A. M.; Clemens-Smith, A.; Del Prado, M.; Dieckman, D. K.;. Dominguez, E.; Escribano, A.; Hoo, K. H.; Hudziak, K. J.; Katofiasc, M. A.; Martinez-Perez, J. A.; Mateo, A.; Mathes, B. M.; Mattiuz, E. L.; Ogden, A. M. L.; Phebus, L. A.; Stack, D. R.; Stratford, R. E.; Ornstein, P. L. Ethyl (3S,4aR,6S8aR)-6-(4-Ethoxycarbonylimidazol-1-ylmethyl)decahydroisoquinoline-3- carboxylic ester: A prodrug of a GluR5 KA receptor antagonist active in two animal models of acute migraine. J. Med. Chem. 2002, 45, 4383-4383.
22. Ornstein, P. L.; Arnold, M. B.; Augenstein, N. K.; Paschal, J. W. Syntheses of 6-oxodecahydroquinoline-3-carboxylates. Useful intermediates for the preparation of conformationally defined excitatory amino acid antagonists. J. Org. Chem. 1991, 56, 4388-4392
23. Mitsunobu, O.; Yamada, M. Bull. Chem. Soc. Jpn. 1967, 40, 2380.
24. Patent WO 01/02367 A2, 2001 (on prodrugs).
25. Small, B.; Thomas, J.; Kemp, M.; Hoo, K.; Ballyk, B.; Deverill, M.; Ogden, A. M.; Rubio, A.; Pedregal, C.; Bleakman, D. LY339434, a GluR5 KA receptor agonist. Neuropharmacology 1998, 37, 1261-1267.
26. Sheardown, M. J.; Nielsen, E. Ø.; Hansen, A. J.; Jacobsen, P.; Honoré, T. 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia. Science 1990, 247, 571-574.
27. For experimental methods, see Supporting Information.